Novanta Inc NOVT
The biggest changes in the 10-K filed Feb 23, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Cash from operations
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“The increase in operating income was primarily due to an increase in gross profit of $4.5 million, a decrease in restructuring, acquisition and related costs of $1.8 million, a decrease in amortization expense of $1.4 million, and a decrease in R&D expenses of $1.2 million, partially offset by an increase in SG&A expenses of $0.9 million.”
Read it in the 10-K
“The decrease in operating income was primarily due to an increase in SG&A expenses of $6.2 million, an increase in restructuring, acquisition and related costs of $5.5 million, an increase in amortization expenses of $3.1 million as a result of our 2025 acquisition, and an increase in R&D expenses of $1.2 million, partially offset by an increase in gross profit of $9.7 million.”
Read it in the 10-K
Net income
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Dec 31, 2025 vs Dec 31, 2024
“Automation Enabling Technologies segment revenue in 2025 increased by $10.2 million, or 2.1%, versus 2024, primarily due to a $30.3 million increase in revenue from our robotics and automation products, partially offset by a $20.0 million decline in revenue from our precision manufacturing products.”
Read it in the 10-K
“Medical Solutions segment revenue in 2025 increased $21.1 million, or 4.6%, versus 2024, primarily driven by a $33.7 million increase in revenue from our advanced surgery products, partially offset by a $12.6 million decline in precision medicine products.”
Read it in the 10-K
Gross margin
Change, FY to Dec 31, 2025 vs Dec 31, 2024
“Automation Enabling Technologies segment gross profit for 2025 increased $4.5 million, or 1.9%, versus 2024, primarily due to an increase in revenue.”
Read it in the 10-K
“Medical Solutions segment gross profit for 2025 increased by $9.7 million, or 5.1%, versus 2024, primarily due to an increase in revenue.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +3.3%
“Automation Enabling Technologies segment revenue in 2025 increased by $10.2 million, or 2.1%, versus 2024, primarily due to a $30.3 million increase in revenue from our robotics and automation products, partially offset by a $20.0 million decline in revenue from our precision manufacturing products.”
Read it in the FY 2025 10-K“Medical Solutions segment revenue in 2025 increased $21.1 million, or 4.6%, versus 2024, primarily driven by a $33.7 million increase in revenue from our advanced surgery products, partially offset by a $12.6 million decline in precision medicine products.”
Read it in the FY 2025 10-K -
FY 2024 +7.7%
“Automation Enabling Technologies segment revenue in 2024 decreased by $8.6 million, or 1.7%, versus 2023, primarily due to a decrease in demand in advanced industrial markets.”
Read it in the FY 2024 10-K“Medical Solutions segment revenue in 2024 increased $76.2 million, or 19.9%, versus 2023, primarily due to revenue from our 2024 acquisition, and an increase in sales from our advanced surgery products, partially offset by a decrease in revenue from our precision medicine products.”
Read it in the FY 2024 10-K
Gross margin
2 of 2 years explained-
FY 2025 -0.0 pts
“Automation Enabling Technologies segment gross profit for 2025 increased $4.5 million, or 1.9%, versus 2024, primarily due to an increase in revenue.”
Read it in the FY 2025 10-K“Medical Solutions segment gross profit for 2025 increased by $9.7 million, or 5.1%, versus 2024, primarily due to an increase in revenue.”
Read it in the FY 2025 10-K -
FY 2024 -0.9 pts
“Automation Enabling Technologies segment gross profit for 2024 increased $0.2 million, or 0.1%, versus 2023, primarily due to an increase in gross profit margin, partially offset by a decrease in revenue.”
Read it in the FY 2024 10-K“Medical Solutions segment gross profit for 2024 increased by $19.2 million, or 11.2%, versus 2023, primarily due to an increase in revenue.”
Read it in the FY 2024 10-K
Operating margin
2 of 2 years explained-
FY 2025 -2.1 pts
“The increase in operating income was primarily due to an increase in gross profit of $4.5 million, a decrease in restructuring, acquisition and related costs of $1.8 million, a decrease in amortization expense of $1.4 million, and a decrease in R&D expenses of $1.2 million, partially offset by an increase in SG&A expenses of $0.9 million.”
Read it in the FY 2025 10-K“The decrease in operating income was primarily due to an increase in SG&A expenses of $6.2 million, an increase in restructuring, acquisition and related costs of $5.5 million, an increase in amortization expenses of $3.1 million as a result of our 2025 acquisition, and an increase in R&D expenses of $1.2 million, partially offset by an increase in gross profit of $9.7 million.”
Read it in the FY 2025 10-K -
FY 2024 -0.9 pts
“The increase in operating income was primarily due to a decrease in restructuring, acquisition and related costs of $6.8 million, a decrease in R&D expenses of $4.0 million, and a decrease in amortization expense of $1.7 million, partially offset by an increase in SG&A expenses of $2.6 million.”
Read it in the FY 2024 10-K“The decrease in operating income was primarily due to a decrease in gross profit of $10.2 million, and an increase in restructuring, acquisition and related costs of $6.8 million, partially offset by a decrease in amortization expense of $4.7 million, a decrease in R&D expenses of $2.4 million, and a decrease in SG&A expenses of $0.7 million.”
Read it in the FY 2024 10-K
Net income
1 of 2 years explained-
FY 2025 -16.0%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 -12.1%
“Our effective tax rate for 2024 differed from the Canadian statutory rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, $3.0 million benefit for foreign derived intangible income, $4.0 million benefit from U.K. patent box deductions and $2.6 million benefit from R&D and other tax credits, partially offset by a $1.9 million increase in valuation allowances and a $1.7 million detriment related to disallowed compensation.”
Read it in the FY 2024 10-K
Cash from operations
0 of 2 years explained-
FY 2025 -59.6%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +32.0%
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NOVT/export.csv") into a cell.